Registered Members Login:
   
Forgotten Your Details? Click Here To Recover +
Welcome To The ShareCafe Community - Talk Shares And Take Stock With Smart Investors - New Here? Click To Register >

972 Pages (Click to Jump) V  « < 969 970 971 972   
 
  
Reply to this topic

AAH, ARANA THERAPEUTICS LIMITED
kiril
post Posted: Nov 18 2003, 09:52 AM
  Quote Post


Posts: 893
Thanks: 262


It is good news for the long term as it will bring them one step closer to resolution.

However they expect it to take 12-18 months.

Kiril


 
nkarp
post Posted: Nov 18 2003, 09:49 AM
  Quote Post


Posts: 35
Thanks: 1


hopefully ptd organised something similar.



Investors piled into Genetic Technologies yesterday after the biotech company announced that two US groups it was suing for patent infringement had settled out of court.

The win leaves only one outstanding lawsuit over Genetic Technologies' claim to have patent control over methods for researching non-coded, or "junk", DNA.

Genetic Technologies shares soared 14 per cent to 58¢ before settling at 56¢, up 5¢ on the day. More than 6 million shares were traded in a stock that typically has daily volumes of less than 500,000.

The Melbourne-based Genetic Technologies has consistently warned it would sue any company, research institution or university that infringed its patent over the so-called junk DNA.

In the past, scientists concentrated on a tiny 1.5 per cent slice of the human genome, dismissing the remaining 98.5 per cent DNA system as useless.

But since early sequences of the human genome were released in 2000, scientists around the world realised the non-coded sections of DNA played a role in switching particular genes on and off and so were crucial in finding cures for gene-related diseases.


advertisement

advertisement

Genetic Technologies founder and executive chairman Mervyn Jacobson said his team pounced on the unwanted DNA and successfully bought the patent covering the non-coded DNA of every living creature, including humans.

Speaking from his home in Colorado, Dr Jacobson said Genetic Technologies had settled its court case with Nuvelo and Covance, though details of the settlement were confidential.

The outstanding lawsuit is with US biotech giant Applera Corporation, and Dr Jacobson said he was determined to go all the way to a final judgement to protect the company's patents.

He said a win against Applera, which has annual sales of more than $US2 billion ($A2.8 billion), could be a warning to any other company considering an infringement of the patents.

Dr Jacobson said Genetic Technologies had sold more than a dozen licences to institutions to enable them to use its patent to conduct research on non-coded DNA.


 
nkarp
post Posted: Nov 18 2003, 09:20 AM
  Quote Post


Posts: 35
Thanks: 1


geez i hope so. but still nervous.
look wats happened and happening to nal!

interesting, CAT in uk just annonced legal action v abbott as well, i take that as a good sign.

go the pep!

 
Bryce
post Posted: Nov 17 2003, 10:47 PM
  Quote Post


Posts: 1,026
Thanks: 38


TheAdder, mate you are everywhere, PTD looks good, healthy rise a coming. cool.gif

 
Guest_andrew_*
post Posted: Nov 17 2003, 03:25 PM
  Quote Post





has anyone heard anything new? what is your expectations and current sentiment on PTD?

 
colaiscute
post Posted: Nov 17 2003, 12:12 PM
  Quote Post


Posts: 690
Thanks: 4


Trading halt announced today.

If it is positive, I dont feel it would be about abbott, as I dont see them caving in so quick.

If positive more likely to be about Centacor.

Could be a placement, or a CEO, or possibly something regarding animal health.

The rise over the last week indicates that the announcement at least has the potential to be good. The big traders over the last week might not have known the details and we be in for a bid dissapointment! mad.gif

I hold.

Hoping for the best. Might be a buying opportunity after a placement price fall.



--------------------
colaiscute
 


colaiscute
post Posted: Nov 17 2003, 12:09 PM
  Quote Post


Posts: 690
Thanks: 4


NEW DATA SHOW ABBOTT LABORATORIES' HUMIRA® (ADALIMUMAB) SIGNIFICANTLY IMPROVES QUALITY OF LIFE IN RHEUMATOID ARTHRITIS PATIENTS

— RESEARCH SHOWS SIGNIFICANT IMPROVEMENT IN PHYSICAL FUNCTION, FATIGUE AND OTHER HEALTH-RELATED QUALITY OF LIFE MEASURES —


Orlando, Florida, October 27, 2003 — New data being presented this week at the annual American College of Rheumatology (ACR) meeting, show Abbott Laboratories' HUMIRA (adalimumab) significantly improved quality of life for people living with rheumatoid arthritis (RA). For the more than five million people worldwide with RA performing simple daily activities, such as climbing stairs or getting out of bed in the morning, is often difficult, if not impossible.

"RA takes an enormous toll on quality of life for people with RA, and fatigue alone can severely limit normal function," said Vibeke Strand, M.D., Stanford University, Palo Alto, Calif. and lead author of the abstract. "These studies show patients on HUMIRA were able to perform everyday activities and also experienced a significant reduction in fatigue, one of the most common and debilitating RA-related symptoms."

Study Design
Data were collected from three pivotal Phase III, double-blind, randomized trials in patients treated with HUMIRA (40 mg) every other week or placebo. At the start of the trials, all patients had active RA despite treatment with methotrexate (MTX) or standard anti-rheumatic therapy. The common tools used to measure quality of life included:

The Health Assessment Questionnaire Disability Index (HAQ DI), a measure of physical function that captures patients' assessment of daily living activities such as grooming, dressing and walking. HAQ DI scores range from 0-3, with lower scores indicating higher levels of physical function.
The Short Form 36-item Health Survey (SF36), a 36-point questionnaire that measures patients' assessment of physical and mental health. The results are based on two component scores: a physical health score, which tracks physical functioning, bodily pain and general health; and a mental health score, which tracks vitality, social functioning and emotional well-being.
Additionally, the studies measured improvements in fatigue using the Functional Assessment of Chronic Illness Therapy fatigue score (FACIT-F), which is designed to measure patients' assessment of fatigue-related factors, such as physical energy and effort required to complete daily tasks such as getting dressed or driving a car.

Results
In all three trials, patients treated with HUMIRA 40 mg every other week showed statistically significant and clinically meaningful improvement in health-related quality of life measures, including physical function, bodily pain and fatigue, compared with placebo, in people with active RA. Results showed:

HAQ Disability Index - The mean improvement from baseline for patients receiving HUMIRA 40 mg every other week was - 0.58, - 0.56 and - 0.51 at 24 weeks versus - 0.23, - 0.24 and - 0.26 for placebo (p<0.001 vs. placebo).
SF-36 - The greatest improvements were seen in physical function, bodily pain, vitality domains and the physical component summary score.
FACIT fatigue scores – Based on FACIT-F scale assessments, HUMIRA is the only biologic to demonstrate statistically significant reduction in fatigue in RA patients. At 24 weeks, patients receiving HUMIRA showed improved scores of 8.1, 7.5, and 6.9 units compared with 2.5, 4.9 and 3.2 units for placebo patients (p<0.01 minimum clinically important differences [MCID]=4).
"Having practiced rheumatology for almost 20 years, I have seen firsthand the impact fatigue and the inability to complete daily activities has on RA patients," said James B. Lefkowith, M.D., divisional vice president, Immunology Development, Abbott Laboratories. "We are encouraged by these findings, which substantiate that HUMIRA significantly improves quality of life."

About RA
RA is a chronic autoimmune disease that affects more than five million people worldwide, with women accounting for three out of four cases. RA causes pain, swelling and stiffness in the joints of hands, feet and wrists, and often leads to the destruction of joints. Unlike osteoarthritis, the "wear and tear" joint condition and most common form of arthritis, RA is an autoimmune disease where joints are inflamed, often resulting in eventual destruction of the joint's interior and erosion of the surrounding bone. The long-term prognosis for RA patients can be poor, and many patients face disability and premature death. Quality of life is seriously affected as RA progresses. Many people with RA experience fatigue, which can be extreme and limit normal activity. Sufferers also endure pain that can interfere with daily function, missed workdays, and feelings of helplessness and depression.

Important Safety Information
Cases of tuberculosis (TB), frequently disseminated or extra pulmonary at clinical presentation, have been observed in patients receiving HUMIRA. Serious infections and sepsis, including fatalities, have been reported with the use of TNF-blocking agents, including HUMIRA. Many of these infections occurred in patients on concomitant immunosuppressive therapy that in addition to their underlying disease could predispose them to infections. Other invasive opportunistic fungal infections have also been observed in patients treated with TNF-blocking agents, including HUMIRA.

TNF-blocking agents, including HUMIRA, have been associated in rare cases with exacerbation of demyelinating disease. The most frequent adverse events seen in the placebo-controlled clinical trials (HUMIRA vs. placebo) were injection site reactions (20 percent vs. 14 percent) upper respiratory infection (17 percent vs. 13 percent), injection site pain (12 percent vs. 12 percent), headache (12 percent vs. 8 percent), rash (12 percent vs. 6 percent) and sinusitis (11 percent vs. 9 percent). Discontinuations due to adverse events were 7 percent for HUMIRA and 4 percent for placebo. As with any treatment program, the benefits and risks of HUMIRA should be carefully considered before initiating therapy.

About HUMIRA
HUMIRA is the first human monoclonal antibody approved by the U.S. Food and Drug Administration (FDA) for reducing the signs and symptoms and inhibiting the progression of structural damage in adults with moderately to severely active rheumatoid arthritis (RA) who have had insufficient response to one or more disease modifying antirheumatic drugs (DMARDs). HUMIRA can be used alone or in combination with methotrexate (MTX) or other DMARDs. HUMIRA was created using phage display technology, resulting in an antibody with human-derived heavy and light chain variable regions and human IgG1:K constant regions.

On September 10, 2003, the European Commission granted marketing authorization to HUMIRA for the treatment of adult rheumatoid arthritis (RA). With E.U. marketing authorization, HUMIRA became the first human monoclonal antibody approved in Europe for RA, and the first tumor necrosis factor alpha (TNF-a) antagonist approved with an indication for use with methotrexate or as monotherapy. In the E.U., HUMIRA is indicated for the treatment of moderate to severe active RA in adult patients when the response to disease modifying anti-rheumatic drugs (DMARDs), including methotrexate, has been inadequate.

On October 1, 2003, HUMIRA submitted a supplemental Biologics Licensing Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval for the use of HUMIRA to improve physical function in patients with moderately to severely active rheumatoid arthritis.

Clinical trials are also currently underway evaluating the potential of HUMIRA in other autoimmune disease.

HUMIRA was discovered through a broad scientific collaboration between Abbott and Cambridge Antibody Technology (CAT). As part of the collaboration, Abbott had the right to select several target antigens for which a joint Abbott/CAT research team would discover human antibody therapeutics. HUMIRA was isolated and optimized by Abbott and CAT as part of this collaboration. Abbott owns exclusive worldwide rights to HUMIRA, including responsibility for clinical development, manufacturing, sales and marketing. Abbott will book all revenues for HUMIRA, and CAT will receive a royalty fee based on HUMIRA sales.

Abbott's Commitment to Immunology
Abbott is focused on the discovery and development of innovative treatments for immunologic diseases, like RA. The Abbott Bioresearch Center, founded in 1989 in Worcester, Massachusetts, U.S., is a world-class discovery and basic research facility committed to finding new treatments for autoimmune diseases.

As part of its commitment to the research and treatment of immunological diseases, Abbott developed The Abbott Scholar Award, which provides funding to researchers in the early stages of their careers to promote career development and encourage continued research in rheumatology.

Additionally, Abbott and the ACR Research and Education Foundation collaborating to develop new opportunities for medical residents interested in the field of rheumatology. This collaboration – supported by a $4.5 million endowment from Abbott, the largest one-time gift that the Foundation has received to date – is designed to ensure the continued recruitment of rheumatologists and rheumatology health professionals for years to come.

More information about Abbott Immunology and HUMIRA, including full prescribing information, is available on the Web sites, www.abbottimmunology.com and www.HUMIRA.com", or in the United States by calling Abbott Medical Information at 1-800-633-9110.

Patients interested in more information about RA can visit the Web site, www.RA.com.

About Abbott
Abbott Laboratories is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals, nutritionals, and medical products, including devices and diagnostics. The company employs more than 70,000 people and markets its products in more than 130 countries. In 2002, the company's sales were $17.7 billion.



--------------------
colaiscute
 
theadder
post Posted: Nov 16 2003, 09:07 PM
  Quote Post


Posts: 5,264
Thanks: 1136


IP from the USPTO site for Peptech

US patents

6593458 Tumor necrosis factor peptide binding antibodies
6,416,757 Tumor necrosis factor antibodies
6,498,237 Tumor necrosis factor antibodies
6,451,983 Tumor necrosis factor antibodies
6,448,380 Tumor necrosis factor antibodies
5,959,087 Tumour necrosis factor binding ligands
5,644,034 Tumour necrosis factor binding ligands
6,375,928 Neutrophil stimulating peptides
6,337,318 Sustained GnRH peptide-release formulation
6,211,152 Formulations for peptide release
5,925,619 Formulation for peptide release
5,877,147 Compounds for medicinal use
5,534,492 Muramyl peptide for the treatment of toxicity
5,506,204 Muramyl compounds for treatment of septic shock
6,376,688 Modified polyunsaturated fatty acids
5,506,204 Muramyl compounds for treatment of septic shock
6,262,119 Methods of treating immunopathologies using polyunsaturated fatty acids
6,121,237 Neutrophil stimulating peptides
5,998,476 Synthetic polyunsaturated fatty acid analogues
5,798,335 Method for the treatment or prevention of eczema/dermatitis
5,795,859 Peptide which abrogates TNF and/or LPS toxicity
5,795,858 Treatment or prevention of Crohn's disease and/or ulcerative colitis
5,767,156 Polyunsaturated fatty acids and uses thereof
5,756,449 Peptide T and related peptides in the treatment of inflammation, including inflammatory bowel disease
5,587,457 Neutrophil stimulating peptides
5,561,110 Method for the treatment of the complications and pathology of diabetes
5,545,408 Biocompatible implant for the timing of ovulation in mares


US patent applications/publications pending

10/264,844 Tumour necrosis factor binding ligands
10/265,344 Tumour necrosis factor binding ligands
10/265,451 Tumour necrosis factor binding ligands
10/320,898 Tumour necrosis factor binding ligands
10/320,940 Tumour necrosis factor binding ligands
10/321,070 contents hidden
10/327,346 Tumour necrosis factor binding ligands
10/327,351 Tumour necrosis factor binding ligands
10/327,541 contents hidden
10/342,589 Tumour necrosis factor binding ligands
10/342,594 Tumour necrosis factor peptide binding antibodies
10/342,624 contents hidden
10/342,631 contents hidden
10/342,740 Tumour necrosis factor peptide binding antibodies
10/346,299 Tumour necrosis factor peptide binding antibodies
10/346,400 Tumour necrosis factor peptide binding antibodies
10/346,498 contents hidden
10/346,499 contents hidden
10/359,934 contents hidden
10/453,176 contents hidden
09/991,714 Sustained peptide-release formulation
10/119,621 abandoned...Neutrophil stimulating peptides
10/100,490 Anti-inflammatory nitro and thia-fatty acids
10/100,274 Anti-cancer nitro- and thia-fatty acids




 
colaiscute
post Posted: Nov 16 2003, 12:46 PM
  Quote Post


Posts: 690
Thanks: 4


PEPTECH LIMITED



--------------------
colaiscute
 
 


972 Pages (Click to Jump) V  « < 969 970 971 972

Back To Top Of Page
Reply to this topic


You agree through the use of ShareCafe, that you understand and accept the TERMS OF USE.


TERMS OF USE  -  CONTACT ADMIN  -  ADVERTISING